|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] efavirenz results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:74,424,620...74,520,646
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression decreases secretion |
ISO |
efavirenz results in decreased expression of ADIPOQ mRNA efavirenz results in decreased secretion of ADIPOQ protein |
CTD |
PMID:21619898 |
|
NCBI chr11:91,226,524...91,240,244
|
|
G |
Alb |
albumin |
affects binding |
ISO |
efavirenz binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,891,564...17,907,043
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases response to substance increases expression |
ISO |
BCL2L11 protein results in increased susceptibility to efavirenz metabolite efavirenz metabolite results in increased expression of BCL2L11 mRNA; efavirenz metabolite results in increased expression of BCL2L11 protein; efavirenz results in increased expression of BCL2L11 mRNA; efavirenz results in increased expression of BCL2L11 protein |
CTD |
PMID:21958719 |
|
NCBI chr 3:135,820,042...135,857,330
|
|
G |
Canx |
calnexin |
affects localization |
ISO |
efavirenz affects the localization of CANX protein |
CTD |
PMID:28940366 |
|
NCBI chr10:35,124,941...35,157,954
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
efavirenz metabolite results in increased cleavage of and results in increased activity of CASP3 protein; efavirenz results in increased cleavage of and results in increased activity of CASP3 protein [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein] |
CTD |
PMID:21958719 PMID:36309141 |
|
NCBI chr16:52,395,539...52,413,794
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in decreased activity of CAT protein |
CTD |
PMID:34118364 |
|
NCBI chr 3:110,297,340...110,329,526
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
efavirenz results in increased secretion of CCL2 protein |
CTD |
PMID:21619898 |
|
NCBI chr10:67,503,077...67,504,875
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
efavirenz results in decreased expression of CEBPA mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 1:87,759,631...87,762,303
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects metabolic processing increases metabolic processing multiple interactions decreases activity |
ISO |
CYP2B6 gene polymorphism affects the metabolism of efavirenz; CYP2B6 protein affects the metabolism of efavirenz CYP2B6 protein results in increased metabolism of efavirenz [efavirenz results in decreased activity of CYP2B6 protein] which results in decreased metabolism of Bupropion; [efavirenz results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [efavirenz results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:15622315 PMID:15769884 PMID:17041008 PMID:17559344 PMID:26599973 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
efavirenz results in decreased activity of CYP2C19 protein |
CTD |
PMID:11225565 |
|
NCBI chr 1:247,879,058...247,916,804
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity increases activity increases expression |
ISO |
efavirenz results in decreased activity of CYP3A4 protein efavirenz results in increased activity of CYP3A4 protein efavirenz results in increased expression of CYP3A4 mRNA |
CTD |
PMID:15980690 PMID:16837568 |
|
NCBI chr12:14,321,771...14,343,886
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
efavirenz results in increased expression of DDIT3 protein |
CTD |
PMID:28940366 |
|
NCBI chr 7:65,001,695...65,006,517
|
|
G |
Dnm1l |
dynamin 1-like |
affects localization |
ISO |
efavirenz affects the localization of DNM1L protein modified form |
CTD |
PMID:28940366 |
|
NCBI chr11:98,084,049...98,135,663
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
ISO |
efavirenz results in increased expression of EIF2AK3 protein modified form |
CTD |
PMID:28940366 |
|
NCBI chr 4:104,363,838...104,425,271
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
ISO |
efavirenz results in increased expression of FIS1 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr12:25,345,239...25,360,135
|
|
G |
Hgf |
hepatocyte growth factor |
increases secretion |
ISO |
efavirenz results in increased secretion of HGF protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:19,628,902...19,700,467
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
efavirenz promotes the reaction [VDAC1 protein binds to HSPA9 protein] |
CTD |
PMID:28940366 |
|
NCBI chr18:26,536,131...26,554,294
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein] |
CTD |
PMID:36309141 |
|
NCBI chr 3:137,030,200...137,036,581
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
efavirenz results in increased secretion of IL6 protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:5,889,999...5,894,575
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases phosphorylation |
ISO |
efavirenz metabolite results in increased phosphorylation of JUN protein; efavirenz results in increased phosphorylation of JUN protein |
CTD |
PMID:21958719 |
|
NCBI chr 5:115,009,900...115,012,993
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
efavirenz results in decreased expression of LEP mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:58,626,529...58,640,663
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
multiple interactions increases response to substance increases expression |
ISO |
efavirenz results in increased expression of and affects the localization of LONP1 protein; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [efavirenz results in increased expression of LONP1 mRNA] LONP1 protein results in increased susceptibility to efavirenz |
CTD |
PMID:28940366 |
|
NCBI chr 9:1,447,444...1,459,771
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
efavirenz results in decreased expression of LPL mRNA |
CTD |
PMID:21619898 |
|
NCBI chr16:25,596,205...25,621,928
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
increases phosphorylation |
ISO |
efavirenz metabolite results in increased phosphorylation of MAP3K5 protein; efavirenz results in increased phosphorylation of MAP3K5 protein |
CTD |
PMID:21958719 |
|
NCBI chr 1:16,505,387...16,723,899
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [efavirenz metabolite results in increased phosphorylation of MAPK8 protein]; Acetylcysteine inhibits the reaction [efavirenz results in increased phosphorylation of MAPK8 protein] efavirenz metabolite results in increased phosphorylation of MAPK8 protein; efavirenz results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:21958719 |
|
NCBI chr16:8,645,171...8,728,225
|
|
G |
Mfn2 |
mitofusin 2 |
increases expression |
ISO |
efavirenz results in increased expression of MFN2 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr 5:158,304,285...158,335,502
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of MPO protein |
CTD |
PMID:34118364 |
|
NCBI chr10:73,092,124...73,102,057
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
EXP |
efavirenz results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr11:75,965,717...76,006,733
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases activity |
ISO EXP |
[efavirenz results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [efavirenz results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 PMID:27732639 |
|
NCBI chr13:86,165,327...86,170,362
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
increases expression |
ISO |
efavirenz results in increased expression of OPA1 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr11:84,612,943...84,690,025
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
efavirenz results in decreased expression of PPARG mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:150,095,743...150,221,104
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
increases expression |
ISO |
efavirenz results in increased expression of RMDN3 protein |
CTD |
PMID:28940366 |
|
NCBI chr 3:126,579,811...126,601,016
|
|
G |
Serpine1 |
serpin family E member 1 |
increases secretion |
ISO |
efavirenz results in increased secretion of SERPINE1 protein |
CTD |
PMID:21619898 |
|
NCBI chr12:25,237,977...25,248,356
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
[efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 protein |
CTD |
PMID:16030158 |
|
NCBI chr16:18,546,709...18,556,698
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
efavirenz results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21619898 |
|
NCBI chr10:45,507,152...45,529,164
|
|
G |
Tg |
thyroglobulin |
increases expression |
ISO |
efavirenz results in increased expression of TG mRNA; efavirenz results in increased expression of TG protein |
CTD |
PMID:16030158 |
|
NCBI chr 7:98,418,293...98,603,210
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein] |
CTD |
PMID:36309141 |
|
NCBI chr20:3,626,685...3,629,303
|
|
G |
Tpo |
thyroid peroxidase |
increases expression |
ISO |
efavirenz results in increased expression of TPO mRNA; efavirenz results in increased expression of TPO protein |
CTD |
PMID:16030158 |
|
NCBI chr 6:52,425,998...52,495,793
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 protein; efavirenz promotes the reaction [TSHB protein affects the abundance of Iodine]; sodium perchlorate inhibits the reaction [efavirenz promotes the reaction [TSHB protein affects the abundance of Iodine]] |
CTD |
PMID:16030158 |
|
NCBI chr 2:190,224,676...190,229,559
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
increases expression |
ISO |
efavirenz results in increased expression of TSHR mRNA |
CTD |
PMID:16030158 |
|
NCBI chr 6:116,072,321...116,206,009
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
efavirenz promotes the reaction [VDAC1 protein binds to HSPA9 protein] |
CTD |
PMID:28940366 |
|
NCBI chr10:37,029,377...37,060,542
|
|